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Abstract
Axonal loss is the key pathological substrate of neurological disability in demyelinating disorders, including multiple sclerosis 
(MS). However, the consequences of demyelination on neuronal and axonal biology are poorly understood. The abundance 
of mitochondria in demyelinated axons in MS raises the possibility that increased mitochondrial content serves as a compen-
satory response to demyelination. Here, we show that upon demyelination mitochondria move from the neuronal cell body 
to the demyelinated axon, increasing axonal mitochondrial content, which we term the axonal response of mitochondria to 
demyelination (ARMD). However, following demyelination axons degenerate before the homeostatic ARMD reaches its 
peak. Enhancement of ARMD, by targeting mitochondrial biogenesis and mitochondrial transport from the cell body to axon, 
protects acutely demyelinated axons from degeneration. To determine the relevance of ARMD to disease state, we examined 
MS autopsy tissue and found a positive correlation between mitochondrial content in demyelinated dorsal column axons 
and cytochrome c oxidase (complex IV) deficiency in dorsal root ganglia (DRG) neuronal cell bodies. We experimentally 
demyelinated DRG neuron-specific complex IV deficient mice, as established disease models do not recapitulate complex 
IV deficiency in neurons, and found that these mice are able to demonstrate ARMD, despite the mitochondrial perturbation. 
Enhancement of mitochondrial dynamics in complex IV deficient neurons protects the axon upon demyelination. Conse-
quently, increased mobilisation of mitochondria from the neuronal cell body to the axon is a novel neuroprotective strategy 
for the vulnerable, acutely demyelinated axon. We propose that promoting ARMD is likely to be a crucial preceding step for 
implementing potential regenerative strategies for demyelinating disorders.
Keywords Multiple sclerosis · Mitochondria · Demyelination and neuroprotection
Introduction
Demyelination leads to the damage and loss of axons and 
the progression of neurological disability in demyelinating 
disorders, including multiple sclerosis (MS) [17, 47, 70]. In 
inflammatory demyelinating disorders such as MS, axons 
are damaged during acute demyelination, and they can also 
degenerate over much longer timescale due to chronic lack 
of myelin [70]. There are no neuroprotective strategies to 
preserve the acutely demyelinated axon, highlighting a major 
and urgent unmet clinical need.
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Myelination enables saltatory conduction of action poten-
tials and conserves neuronal energy by clustering voltage-
gated  Na+ channels to the nodes of Ranvier [47]. In con-
trast, the demyelinated axon is bioenergetically challenged, 
and has an increased reliance on the  Na+/K+-ATPase, and 
therefore ATP, to maintain the resting membrane potential 
and axonal integrity due to the redistribution of ion chan-
nels [76]. In particular, sodium channels redistribute along 
the axolemma following demyelination, which leads to an 
excess of sodium influx in to the axon. When ATP is not 
readily available, an excessively high sodium concentration 
in the axon leads to the reversal of  Na+/Ca2+ exchanger and 
accumulation of calcium, which activates calcium dependent 
proteases and degeneration of the demyelinated axon [76]. 
One underlying mechanism that contributes to the degenera-
tion of demyelinated axons, likely both acute and chronic, is 
an imbalance between the increased energy demand of nerve 
conduction and the generation of ATP in the demyelinated 
axon [37, 71].
ATP needed to meet the increased energy demand of the 
demyelinated axon is most efficiently produced by mitochon-
dria. Neurons with healthy mitochondria respond to demy-
elination by increasing the mitochondrial content in acutely 
demyelinated axons [37]. The increased mitochondrial con-
tent of demyelinated axons is consistently evident in MS 
autopsy cases and experimental disease models [39, 45, 51, 
57, 77, 81]. Increased axon damage in knockout mice, where 
the axonal mitochondrial content fails to increase following 
demyelination, due to the lack of a docking protein (syn-
taphilin), suggests that the neuropathological observation of 
increased mitochondrial content in demyelinated axons is an 
attempt to alleviate the energy imbalance [51].
The energy imbalance in demyelinating disorders is fur-
ther exacerbated by the mitochondrial respiratory chain defi-
ciency in neurons, which impairs the capacity to generate 
ATP [37]. In progressive MS, both clonally expanded mito-
chondrial DNA (mtDNA) deletions and decrease in nuclear 
DNA encoded mitochondrial transcripts in neuronal cell 
bodies have been implicated in the mitochondrial respiratory 
chain deficiency [6, 9, 14, 78]. The resulting mitochondrial 
deficiency is likely to hamper the energy producing capacity 
of demyelinated axons together with mitochondrial injury 
that is imposed by inflammation [49, 65]. It remains untested 
whether targeting of neuronal mitochondria with healthy and 
deficient respiratory chain function, might mitigate axonal 
loss following demyelination and address the key substrate 
of neurological disability—the vulnerable axon.
Against this background, we set out to study neuronal 
mitochondria in detail using cerebellar slices, microfluidic 
chambers, established experimental disease models as well 
as autopsy tissue and a novel in vivo model. We discovered a 
homeostatic response, which we termed the axonal response 
of mitochondria to demyelination (ARMD). Enhancement 
of ARMD therapeutically protected acutely demyelinated 
axons. Given the already recognised mitochondrial respira-
tory chain complex IV deficiency in cortical neurons in MS, 
we next studied dorsal root ganglia (DRG) neurons and their 
centrally projecting axons. We identified respiratory defi-
cient DRG neurons and evidence of ARMD in disease. Upon 
modelling, we show that enhancing ARMD in respiratory 
deficient neurons, in vivo, protects these extremely vulner-
able acutely demyelinated axons from degeneration.
Materials and methods
Preparation of cerebellar slice culture
Cerebellar slices were prepared as previously described 
[4]. Briefly, wild type C57BL/6 and Shiverer mice pups 
were sacrificed at P10 and cerebellum was placed in ice-
cold dissection medium. The sagittal slices were then sec-
tioned into 300 µm thick slices and placed on a membrane 
insert. Picospritzer III (Parker, US) and a micromanipula-
tor were used to inject mEOS2-Lentivirus (titre 7–8 ×  109; 
aliquots stored at − 80 °C) containing 0.025% of Fast-
Green (FG, Sigma F7258, UK) in to the Purkinje cell body 
layer. To enhance activation of the CMV-promoter driven 
mEOS2 construct, 10 µM of Forskolin (Forskolin Coleus 
forskohlii, 344282 Sigma) was added to the slice culture 
medium the day after injection and removed 2 days later. 
To demyelinate cerebellar slices, we used lysolecithin (l-α-
lysophosphatidylcholine; L4129 Sigma), which minimally 
impacts mitochondrial function [4]. 0.75 mg/ml Lysolecithin 
was added to the medium for 17 h at DIV13. For the time 
course experiments of the ARMD, 0.5 mg/ml lysolecithin 
was added to the medium for 17 h. The slices were then 
fixed and stained using immunofluorescence histochemistry 
at several timepoints after removal of lysolecithin to deter-
mine changes in axonal mitochondrial parameters and axonal 
bulbs. Only demyelinated axons that were not transected 
were chosen for axonal mitochondrial analysis.
Preparation of viral particles
Cloning and preparation of Lentivirus were performed by 
Pamela Brown as previously described [41]. Miro1 and 
PGC1α plasmids were sourced from Addgene (pRK5-Miro1, 
plasmid #47888; AAV-CMV-Flag-PGC1α-6His, plasmid 
#67637). Miro1 was inserted into a pDONR-P2A-mKate2 vec-
tor. The pDONR-P2A-mKate2 vector was used as a negative 
control and as an axonal marker in live imaging experiments. 
PGC1α was inserted into a pDONR-P2A-eGFP. The m1m4-
eGFP (kind gift from Alan Peterson and Anna Williams) 
was amplified using primers with attB sites and cloned into 
a pDONR vector. All plasmids were shuttled into a lentiviral 
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backbone pLenti6-cppt-delta CMV-DEST-opre, as described 
previously [11]. The viral titers were as follows mEOS2 8.2 × 
 109 cfu/ml, Miro1 5 ×  108 cfu/ml, PGC1α 1.4 ×  108 cfu/ml, 
mKate2 2.25 ×  109 cfu/ml, m1m4-eGFP 6.74 ×  109 cfu/ml.
Live imaging and analysis of axonal mitochondria 
in cerebellar slices and identification 
of demyelinated axons in‑vitro using spectral 
confocal reflectance microscopy (SCoRe)
Live imaging of mitochondria in Purkinje cell axon was 
performed at DIV14, directly after removing the lysoleci-
thin. Mitochondria in the most proximal 50 µm segment 
of the Purkinje cell axon were photoconverted using the 
405 nm laser at 3% laser power for 20 s [34]. Immediately 
after photoconversion, the 85 µm long proximal axonal seg-
ment was imaged every minute for 20 min. An 8–12-μm 
stack was created from images every 0.5 μm in depth. Time 
lapse images were used to generate videos, exported from 
the Zeiss software, while all further analysis was done in 
Fiji [59]. Newly transported mitochondria, either appearing 
from the neuronal cell body to the most proximal 20 μm 
axonal segment or distal axonal mitochondria appearing in 
the 20 μm long axonal segment of the most distal photocon-
verted segment, were counted visually and confirmed using 
the kymograph. Green mitochondria represent newly trans-
ported mitochondria and red labelled mitochondria represent 
pre-existing mitochondria in the proximal axonal segment. 
For each mitochondrion appearing, the direction of move-
ment was noted, as well as the area of the mitochondrion 
was measured manually, using the measure function in Fiji, 
when it first appeared in the axon.
Kymographs of the time lapse images were generated by 
using the ImageJ plugin KymographClear2.0 [40]. Mito-
chondrial speed of movement was determined by using the 
Kymotoolbox ImageJ plugin [80]. The mitochondria moving 
anterograde from the cell body to the axon were identified 
by the slope direction of tracks within the 20 microm of 
the kymograph and subsequently confirmed on the video. 
For retrograde moving mitochondria 20 microm of the most 
distal part was used.
We used spectral confocal reflectance microscopy 
(SCoRe) to determine the myelination status of the axons 
[58]. Specificity of SCoRe, to differentiate demyelinated 
axons from myelinated axons, was confirmed by immuno-
fluorescence staining for Myelin Basic Protein (MBP) and 
neurofilament and then overlapping it with SCoRe image.
Triple immunfluorescent staining and confocal 
imaging of cerebellar slices
The membrane inserts containing cerebellar slices were cut 
out and fixed in PFA before heat mediated antigen retrieval. 
After blocking with Normal goat serum (NGS, Vector 
S-1000, US), the free floating slices were incubated with 
three primary antibodies (Supplementary Table 1, online 
resource), and then exposed to secondary antibodies, before 
mounting using Vectashield with DAPI (Vector H-1200, US) 
[52]. Confocal images of triple staining (Supplementary 
Table 1, online resource) were acquired on a Zeiss LSM 
710 inverted confocal microscope (Zeiss, Germany).
To quantitate axonal mitochondria, images were pro-
cessed in Adobe Photoshop CS6 (Adobe, US) and all non-
axonal mitochondria (outside the NF + structures) were 
removed. Images were then opened in Fiji and individual 
axons were cut out to analyse the axonal mitochondrial 
parameters using macros. The first macro split the images 
into the separate color channels, the second macro measured 
the axonal area and the third macro measured the axonal 
mitochondrial number and area. For each slice, 40 axons 
were chosen and the mean axonal mitochondrial occupancy 
was calculated for each data point, which represents a slice 
from a different animal.
For the analysis of axonal bulbs, images of NF labelling 
were acquired as mentioned above and the axonal bulbs per 
field of view in × 63 images were counted. For each cerebel-
lar slice five fields of view were randomly selected and the 
axonal bulb were counted and averaged for each datapoint.
Triple immunofluorescent staining and confocal 
imaging of mouse spinal cord and MS cryosections
Longitudinal cryosections, 15 microm thickness, of dor-
sal spinal cord were placed on glass slides and stored at 
− 80 °C. The triple immunofluorescent staining and confocal 
images were taken from wild type and mutant mice as well 
as human tissue and followed the same protocol as for the 
cerebellar slices.
For the analysis of axonal mitochondria, only the non-
transected dorsal column axons were included. Acutely 
demyelinated experimental lesions were identified by DAPI 
staining and loss of MBP staining. Chronic MS lesions were 
identified by loss of MBP and serial sections were used for 
the mitochondrial analysis. Images were processed and ana-
lysed as described for cerebellar slices. For calculating mito-
chondrial complex IV deficiency in mouse spinal cord axons 
(wild type and mutant) and human dorsal column axons, the 
mitochondrial channels of complex II 70 kDa and COX-I 
were merged in Fiji. A macro was used to calculate the per-
centage of complex II 70KDa-positive regions that were co-
labelled by COX-I for each axon. For each case, 40 axons 
were chosen and the mean axonal mitochondrial occupancy 
was calculated for each data point, which represents a dif-
ferent animal or human case. Axonal bulbs were quantitated 
as described for cerebellar slices.
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For the analysis of axon number in dorsal columns of WT 
and COX10Adv mutant mice, frozen transverse sections of 
cervical spinal cord were fixed and stained, as described 
previously. The sections were then imaged on a Zeiss 
ApoTome.2 (Zeiss, Germany) with tile scan function and 
stitching to generate a single image file for the whole dorsal 
column. The total axon number per animal was determined 
using “analyse particle” function in FIJI. For the analysis of 
PGC1α-positive nuclei in DRG neurons, snap frozen spinal 
cord was cryosectioned longitudinally, fixed and stained for 
PGC1α, NF200 and peripherin. Images of the whole DRG 
were acquired and the percentage of PGC1α + NF200 + cells 
was determined. For the analysis of mitochondrial respira-
tory chain subunits of the mitochondrial respiratory chain 
within human DRG neurons, we triple stained using NF200, 
complex II 70 kDa and a number of subunits (Supplemen-
tary Table 1, online resource). The percentage of DRG neu-
rons that were deficient in mitochondrial respiratory chain 
subunits was determined in serial sections of human DRG.
Design and fabrication of microfluidic chambers
Microfluidic chambers were fabricated in polydimethyl-
siloxane (PDMS) (Sylgard 184, Dow Corning, US) using 
standard soft lithography techniques, comprising of an array 
of microchannels between two culture chambers that are 
fluidically addressable via inlet/outlet wells, as previously 
described [36]. Prior to use, these devices were coated with 
0.45 mg/ml Matrigel (Corning 356231, US) for 1 h at RT 
and 30 mg/ml Poly-D-lysine (PDL, Sigma Aldrich P6407, 
UK) for 30 min at RT. To achieve fluidic isolation in a given 
chamber we added at least 10 µl more of the medium to the 
opposite chamber, which prevents diffusion from the treated 
to the untreated chamber, as previously shown [55, 56].
Culture of DRG neurons and OPCs in microfluidic 
chambers
DRG neurons were rapidly extracted from P4-P8 old 
C57BL/6 mice pups, as previously described [64]. Differ-
ential adhesion was used to remove excess glial cells from 
the culture. After seeding the DRGs in seeding medium a 
concentration of 20 µM FUDR was added to the DRG neu-
ronal cell body chamber and the axonal chamber to reduce 
growth of non-neuronal cells. A concentration gradient of 
25 ng/ml NGF in the cell body chamber to 50 ng/ml NGF 
in axonal side was created to enhance axonal growth. The 
day after placing DRG neurons in the cell body chamber, the 
seeding medium was completely removed and replaced with 
maintenance medium. Until the 10 day after seeding, FUDR 
was added at a concentration of 10 µM to both sides of the 
chamber, while the NGF gradient was maintained for the 
same period. At 10 days after seeding Lentivirus expressing 
mKate2 was added to the cell body chamber at MOI 25 to 
label DRG neurons in the cell body chamber and their axons 
in the axonal chamber.
OPCs for myelinating cultures were obtained by dissec-
tion of Sprague Dawley rat cortices, as previously described 
[82]. Once cell count was done using a hemocytometer, 
M1-M4-eGFP lentivirus was added at MOI 40 to approxi-
mately 100,000 OPC. Oligodendrocyte precursor cells 
(OPCs) were seeded into the axonal chamber at 12 days 
following DRG seeding in the cell body chamber, in order 
to allow sufficient number of axons to have crossed into 
the cell body chamber [72]. Immediately following seed-
ing of OPCs, the maintenance medium in both chambers 
was replaced with myelination medium [72]. Thereafter co-
cultures were maintained for another 2 weeks, while renew-
ing the myelination medium two times a week, to ensure 
adequate myelination prior to the visualization of myelinated 
axonal segments in live-imaging.
Demyelination of microfluidic chambers 
and analysis of axonal damage and myelin‑status 
in live images
We established that 0.005 mg/ml of lysolecithin for 2 h was 
sufficient to demyelinate DRG-OPC co-cultures without 
damaging the DRG axons in unmyelinated cultures. Before 
adding lysolecithin to microfluidic chambers, we used an 
Axio Observer Z1 inverted motorized microscope (Zeiss, 
Germany), for live imaging to identify the myelinated axonal 
segments (video 11, online resource). Images of the myeli-
nated axonal segments were saved with x–y co-ordinates of 
the stage position. The effect of live imaging on the axons 
and myelin was determined by imaging microfluidic cham-
ber containing both mKate2 expressing DRGs and eGFP-
expressing OPC where imaged at 20 × magnification (Plan-
Apochromat 0.8 NA Ph 2 M27 objective, Zeiss, Germany) 
for 30 min before returning the microfluidic chambers to the 
incubator. Re-imaging 24 h later showed that there was no 
significant effect of live imaging on axonal health.
We then added lysolecithin for 2 h before live imaging 
the previously imaged axonal segments again, using the x–y 
co-ordinate of the stage position. These live images of axons, 
pre and post lysolecithin, allow us to assess the demyelina-
tion of the axonal segments (based on M1-M4-eGFP fluo-
rescence) as well as axonal damage following acute demy-
elination (based on appearance of mKate2 fluorescence). 
Axonal structure was categorized as intact, beaded or frag-
mented, both prior to and following exposure to lysolecithin. 
Intact axons showed continuous mKate2 fluorescence and 
beaded axons showed obvious irregularities in axon diam-
eter without transection. Meanwhile, axons were classed as 
fragmented when the mKate2 fluorescence was disrupted 
and not continuous in at least one part of the axon. Nearly 
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all myelinated axonal segments were intact prior to expo-
sure to lysolecithin and only intact myelinated axons were 
considered for the assessment of axon damage following 
acute demyelination. Following exposure to lysolecithin, 
demyelination was confirmed based on disruption or loss 
of M1-M4-eGFP fluorescence. On average 12 myelinated 
axonal segments were included per microfluidic chamber. 
An average of data from 2–3 microfluidic chambers per 
batch of experiments were pooled to generate a single data 
point presented in Fig. 3.
Manipulating mitochondrial dynamics 
in unmyelinated and myelinated cultures
We targeted anterograde movement of mitochondria in 
unmyelinated DRG neurons, by over expression Mitochon-
drial Rho GTPase1 (Miro1), using a lentivirus [22]. Further-
more, we targeted mitochondrial biogenesis in neurons by 
over expressing peroxisome proliferator-activated receptor 
gamma (PPAR-γ) coactivator 1-alpha (PGC1α), using a len-
tivirus [25, 54]. We then pharmacologically targeted mito-
chondrial biogenesis in neurons by using pioglitazone [44]. 
DRG were extracted as described previously and seeded on 
glass-bottomed 35 mm dish (µ-dish35mm, low Grid-500 
ibiTreat, ibidi 80,156, Germany). Lentivirus Miro1 at MOI 
10 was added to the culture medium at seeding (3 weeks 
before live imaging) and Lentivirus PGC1α at MOI 10 was 
added at 2 and 4 days and 3 weeks before live imaging. 
Finally, 2 µM pioglitazone was added at 2, 4 and 6 days and 
3 weeks before live imaging and renewed with each media 
change. The same manipulations were carried out in DRG 
neurons co-cultured with OPCs, which were added DIV12. 
Myelinated axonal segments were identified for confocal 
imaging using SCoRe, as previously described for cerebel-
lar slices (Supplementary Fig. 1, online resource).
Manipulating axonal mitochondria by targeting 
DRG neuronal cell bodies in microfluidic chambers
In order to avoid pioglitazone impacting oligodendrocyte 
lineage cells and myelinated axons, we applied the drug to 
the DRG neuronal cell body chamber at a concentration of 
2 µM for 6 days prior to demyelination. Pioglitazone was 
renewed in the neuronal cell body chamber with each media 
change. Furthermore, PGC1α inhibitor [15 µM SR-18292 
(SML2146, Sigma UK)] was added together with pioglita-
zone to neuronal cell body chamber [62]. Following 6 days 
of pioglitazone treatment of the neuronal cell bodies, with 
or without PGC1α inhibitor.
Following 6 days of pioglitazone treatment of the neu-
ronal cell bodies we added lysolecithin to the axonal cham-
ber to demyelinate, as previously described.
Lentivirus Miro1 and Lentivirus PGC1α were applied 
to the neuronal cell body chamber at seeding and DIV16, 
respectively. At DIV26, lysolecithin was added to the myeli-
nating chamber, as previously described. Axonal integrity 
of myelinated segments (before demyelination) and axonal 
damage following demyelination (of the same myelinated 
axonal segment) were quantified using live imaging, as pre-
viously described.
Manipulating axonal mitochondria in cerebellar 
slices
The cerebellar slices from wild type C57BL/6 mice pups 
(P10) were prepared as described and the slices were main-
tained on membrane inserts in culture for a week, before 
adding 40 µM pioglitazone (Sigma PHR1632, UK) to the 
culture medium. Two days following exposure to pioglita-
zone, culture medium was renewed and lysolecithin 0.5 mg/
ml was added to the culture medium for 17 h. Following the 
removal of lysolecithin, pioglitazone was replaced in the cul-
ture medium for 3 days until fixing and staining of the slices, 
as previously described. Triple immunofluorescent labelling 
and confocal microscopy were used to assess demyelination 
and axonal bulb formation as well as mitochondrial occu-
pancy of non-transected and demyelinated axons, as previ-
ously described.
Photoconversion of mEOS2 and live imaging 
of axonal mitochondria in DRG neurons
Live imaging of mitochondria located in the proximal seg-
ment of DRG axon, was performed with or without mito-
chondrial manipulations, as described above for cerebellar 
slices. Each data point on the graphs in Fig. 2 represents the 
value of a single axon.
To assess the ARMD response, DRG neurons were 
seeded in microfluidic chambers and mEOS2 lentivirus 
was added at seeding. At DIV12, OPC were added to the 
axonal chamber to achieve myelination, as described pre-
viously. At DIV24, the chambers were imaged on a Leica 
SP8 microscope with temperature control at 37 °C and 5% 
 CO2 flow with a 25 × water immersion objective (Leica). Per 
chamber all mEOS2 positive mitochondria in axons within 
two fields of view in the axonal chamber and the adjacent 
microchannels were then converted using the 405 nm laser 
at 3% laserpower for 2 min. To assess ARMD chambers 
were demyelinated using 0.005 mg/ml lysolecithin for 2 h. 
The chambers were then returned to the incubator overnight. 
The following day photoconverted regions were imaged to 
assess newly transported mitochondria (green) from the cell 
body chamber to the axonal chamber. SCoRe was used to 
determine the myelinated status of the axons. To analyse 
the amount of newly transported green mitochondria in the 
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axonal chamber, 20 axons were randomly selected, cut out 
and saved as single axon images. Fiji was then used to cal-
culate the proportion of green in red area. To calculate the 
axonal mitochondrial occupancy, the “analyse particles” 
function of Fiji was used to determine the mitochondrial 
area, which was then corrected for the length of the axonal 
segment. Each dot in Supplementary Fig. 3, online resource, 
represents an axon.
Assessing the effect of mitochondrial manipulations 
on lysosomal trafficking in unmyelinated DRG 
neurons
To determine the effect of Miro1, PGC1α and pioglitazone 
on lysosomal trafficking in DRG neurons, unmyelinated 
DRG neurons were seeded on glass-bottomed 35 mm dishes, 
as previously described. Miro1 was added at seeding, while 
PGC1α and pioglitazone were added to the DRG neurons at 
10 days and 6 days before imaging, respectively. At DIV14 
LysoTracker (LysoTracker Red DND-99, L7528 Invitro-
gen) was added to the culture medium at a concentration of 
50 nM and incubated for 30 min at 37 °C, before washing 
the LysoTracker off and adding live imaging solution to the 
DRG neurons. Live fluorescence imaging was performed 
as described for microfluidic chambers, using a 63 × oil 
immersion objective (Plan-Apochromat 1.40 NA Oil DIC 
M27 objective, Zeiss, Germany). Videos and Kymographs 
were generated as described previously. The total number 
of lysosomes moving in both directions were counted on 
the kymograph and visually confirmed on the videos and 
the direction of movement for every single lysosome was 
noted. Each datapoint on Fig. 2f and g represents the average 
number of moving lysosomes per axon.
Pharmacological inhibition of complex IV in DRG 
neurons using sodium azide
Sodium azide (Sigma S8032, UK) was used to inhibit com-
plex IV in unmyelinated DRG neurons, cultured on glass 
bottom dishes, as described previously [39]. Firstly, a con-
centration gradient experiment was performed to determine 
the sublethal sodium azide (Sigma S8032, UK) dose for 
DRG neurons, which inhibits complex IV, by trypan blue 
exclusion test [67]. The highest dose, which did not impact 
cell viability and resulted in complex IV inhibition, was 
determined as 100 µM sodium azide for 17 h, which was 
used for all the subsequent complex IV inhibition experi-
ments. Complex IV histochemistry was performed as 
described below and images were obtained using bright 
field microscopy. The intensity of the complex IV reactive 
product was assessed using FIJI and densitometry to analyse 
complex IV activity at a single cell level.
For live imaging of mitochondrial dynamics in complex 
IV deficient DRG neurons, we cultured unmyelinated DRG 
neurons on glass bottom dishes, as described previously. 
Lentivirus mEOS2 was added at seeding and live imaging 
was performed at DIV21, as described previously. Kymo-
graph were prepared and mitochondria were analysis as 
described previously for Purkinje cell axons in cerebellar 
slices.
Complex IV inhibition and Seahorse analysis 
of mitochondrial respiration
DRG neuronal cells were cultured on V7 Seahorse 24-well 
cell culture microplates (Agilent Technologies), in main-
tenance medium in a 5%  CO2 37 °C incubator. Sodium 
azide was present in media at either 0.1 or 1 mM for 17 h 
before the Seahorse experiment, and the sodium azide was 
maintained in the media during the Seahorse run. Plates 
were incubated for 30 min at 37 °C (without  CO2), before 
entry into the Seahorse XFe24 Extracellular Flux Analyser 
(Agilent). Three measurements were taken basally, and 
three measurements taken after injection of each drug to 
either inhibit ATP-linked respiration, uncouple respiration 
or inhibit the respiratory chain. Mitochondrial respiration 
was calculated by subtracting the first OCR measurement 
following injection of antimycin/rotenone from the third 
basal OCR measurement. Normalisation of OCR to rela-
tive protein content was achieved following Sulforhodamine 
B (SRB) staining of all cell wells. Data for each treatment 
groups was averaged from between 4 and 5 replicate wells.
Human tissue
We obtained frozen human autopsy tissue, including dorsal 
root ganglia and spinal cord blocks, from the rapid autopsy 
program at Cleveland Clinic, Ohio, USA and Netherland 
Brain Bank (Table 1). The frozen tissue blocks were stored 
at − 80 °C until cryosectioning. The entire DRG were cryo-
sectioned at 15 microm intervals. Cryosections were then 
subjected to COX/SDH histochemistry, COX/immunofluo-
rescent labeling as well as laser micro dissection of single 
neurons, as described below.
Complex IV/complex II histochemistry and analysis 
of complex IV deficient DRG neurons
Mitochondrial respiratory chain complex IV(COX)/com-
plex II (succinate dehydrogenase [SDH]) activity was 
assessed using the well-established sequential COX/SDH 
histochemistry, as previously described [9]. In five ran-
domly chosen DRG cryosections, complex IV deficient 
neurons (stained blue) were calculated as a percentage 
of total neurons (sum of neurons stained either brown or 
149Acta Neuropathologica (2020) 140:143–167 
1 3
Table 1  Details of human autopsy cases
Case no Age/gender Subtype Disease duration Cause of death PMD C and L
MS1 34/M MS < 24 C3 L3
MS2 41/F SPMS 11 End stage MS (natural death) 8 C6 L2
MS3 56/M SPMS 14 GI bleed 10 C6
MS4 64/M PPMS 34 End stage MS (natural death) 8 L1
MS5 69/F SPMS 26 Viral infection 13 C5 L3
MS6 77/F Progressive MS > 6 years Pneumonia 7 L2
MS7 40/F Progressive relapsing MS 8 Haematemesis 9 L5
MS8 50/F SPMS 17 Euthanasia 7 C8 L1
MS9 53/M SPMS 9 Cardiopulmonary failure 5 L5
MS
10
61/M SPMS 31 Euthanasia 9 L5
MS
11
71/F Progressive MS 23 Respiratory failure 10 L2
MS
12
78/F SPMS 25 Cerebrovascular accident 11 C7 L3
MS
13
81/F SPMS 59 Pneumonia 7 L1
MS
14
82/M SPMS 32 Pneumonia 6 C8
MS
15
88/F PPMS 25 Chronic colitis 8 L5
MS
16
62/F SPMS 43 Pneumonia 6 L
MS
17
70/M SPMS 46 Cardiac arrest 7 L2
MS
18
74/M SPMS 36 Respiratory failure 9 L
CON
1
74/M – – Lung carcinoma 7 L2
CON
2
58/M – – Oligodendroglioma (left parieto-occipital) 5 C L2
CON
3
71/F – – Renal failure 7 C L
CON
4
68/F – – Sepsis 42 L
CON
5
70/M – – Cerebrovascular accident 24 L
CON
6
55/F – – Sepsis 24 L
CON
7
62/F – – Euthanasia (renal cell carcinoma) 8 L2
CON
8
80/M – – Cardiac failure 8 C L1
CON
9
92/F – – Urosepsis 7 L1
CON
10
84/M – – Cardiopulmonary failure 5 L2
CON
11
71/M – – Pneumonia 7 C
CON
12
47/F – – Breast carcinoma 4 C
PD
1
84/M – – Pneumonia 7 L
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blue) in both frozen human (Table 1) and frozen mouse 
tissue (Table 2 and COX10Adv mutant mice). For the 
detection of complex IV deficient cells with intact com-
plex II within the brain spinal cord of the animal models 
(Table 2), we stained every 5th section of the entire brain 
and spinal cord and scanned the sections at 40 × objective 
manually to look for cells stained blue (complex IV defi-
cient with intact complex II).
Sequential COX/immunofluorescent labeling of DRG 
neurons and CNS cells
To identify complex IV in proprioceptive and nociceptive 
DRG neurons, NF200 and peripherin were immunofluores-
cently labeled following completion of complex IV histo-
chemistry step, as previously described [38]. Both bright-
field and fluorescent images of five randomly chosen DRG 
Table 1  (continued)
Case no Age/gender Subtype Disease duration Cause of death PMD C and L
PD
2
84/F – – Old age 6 L
PD
3
79/F – – Renal failure 5 L
MND
1
58/M – – Respiratory failure 6 L
MND
2
74/M – – Pneumonia 7 L
C cervical, CON control, L lumbar, MND motor neuron disease, MS multiple sclerosis, PD Parkinson’s disease, PMD post mortem delay, SPMS 
secondary progressive MS. Human autopsy tissue was obtained from Cleveland Clinic, Netherland Brain Bank and Edinburgh Brain Bank
Table 2  Details of established experimental disease models
DRG dorsal root ganglia. EAE experimental autoimmune encephalomyelitis, LPC lysolecithin, LPS lipopolysaccharide, MOG myelin oligoden-
drocyte glycoprotein, TCR T-cell receptor, TMEV Theiler’s murine encephalomyelitis virus, n number of animals used for brain and spinal cord 
analysis
*Indicates peak clinical disease or peak demyelination time point for the analysis of axonal mitochondrial parameters. All the time points stated 
above were included in the detection for respiratory-deficient cells. Equal numbers of age-matched controls were used, except for marmoset EAE 
where 4 age-matched controls were used
Model (co-author) Species (strain) Time points for analysis in days n = (brain, 
spinal cord, 
DRG)
Focal demyelinating dorsal funiculus lesion:
LPC (1%) [79]
Mouse (C57BL/6) 5* 0, 6, 6
LPS (200 ng) [16] Rat
(Sprague–Dawley)
7* 0, 6, 3
Cuprizone-mediated demyelination of the brain 
[21]
Mouse (C57BL/6) 42*
91
6, 0, 0
6, 0, 0
TMEV-induced inflammatory demyelination [57] Mouse
(SJL/J)
7 (acute encephalitis)
41 (demyelinating)
112 (axonal loss)*
209 (chronic)
3, 3, 3
3, 3, 3
3, 3, 3
3, 3, 3
T-reg depleted active EAE with  MOG35–55 [42] Mouse (C57BL/6) 13 (acute)*
30 (resolution)
60 (chronic)
0,10, 0
0, 7, 0
0,9, 0
Humanized TCR transgenic with spontaneous 
EAE [15]
Mouse (C57BL/6) 120–150*, (clinical score 1–2 and > 3) 3, 3, 0
3, 3, 0
Chronic EAE with subcutaneous spinal cord 
homogenate [2]
Mouse
(Biozzi ABH)
18 (acute)*
35–40 (relapsing)
120 (chronic)
3, 3, 3
3, 3, 3
10, 10, 6
Acute EAE with rMOG [12] Rat
(Dark Agouti, Harlan)
1
3
14*
3, 3, 0
3, 3, 0
3, 3, 3
EAE with  rMOG34–56 [26] Marmoset (Callithrix jacchus) 11 days*, on average, post EAE score of 2.5 9, 5, 2
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cryosections were obtained using Zeiss ApoTome.2 micro-
scope (Zeiss, Germany) and superimposed using ImageJ to 
identify complex IV activity within proprioceptive and noci-
ceptive DRG neurons. Proprioceptive neurons were identi-
fied as NF200 + peripherin-. To identify complex IV defi-
cient CNS cells in animal models, independent of complex II 
activity, we performed sequential COX/immunofluorescent 
histochemistry and used antibodies against COX-I and com-
plex II 70 kDa (Supplementary Table 1, online resource), 
as previously described [38]. To look for immunofluores-
cently labelled cells, we stained every 5th section of the 
entire brain and spinal cord, except marmoset EAE, where 
tissue blocks were used, and manually scanned the sections 
at 40 × objective.
Laser capture of single DRG neurons from MS tissue 
and grey matter from animal models for Real time 
PCR and long range PCR
Cryosections (15 μm thick) were mounted onto membrane 
slides (Leica) for laser micro dissection. Following COX/
SDH histochemistry, single DRG neurons were micro dis-
sected using a Leica laser micro dissection microscope 
(Leica LMD), as previously described [9]. Spinal cord grey 
matter regions from snap frozen tissue was micro dissected 
from animal models (Table 2), except in cuprizone model 
where approximately 250 × 250 μm2 region of cortex was 
included. DNA extraction was carried out using the QIAamp 
DNA Micro Kit (Qiagen).
To analyse the level of mitochondrial DNA deletion in 
single DRG neurons in MS tissue we used a real-time PCR, 
as previously described [9]. Known deletion-level standards, 
a blood-positive control and a blood-negative control, run 
in triplicate, were added to the assays. To detect mtDNA 
deletions in human autopsy tissue and in snap frozen tissue 
from animal models, we used long-range PCR, as previously 
described [9].
Cresyl violet staining of DRG neurons
One in every five serial sections of each DRG was processed 
using cresyl violet staining and the total number of DRG 
neurons with nuclei was counted per DRG section for each 
animal and human case. An average of 4–5 DRG per animal 
and human case was included in each data point shown in 
Supplementary Fig. 6a–c, online resource and Supplemen-
tary Fig. 10a, online resource.
Animal genotyping and focal lesioning of the spinal 
cord dorsal columns
To generate inducible knockout of complex IV subunit 10 
(COX10) in DRG neurons, we crossed  COX10flox/flox mice 
with  AdvillinCreERT2/+ mice to derive  COX10flox/floxAdvil-
linCreERT2/+ mutant mice (COX10Adv mutants) [13, 48]. 
Wild type and COX10Adv mutant mice were maintained 
on C57Bl6 background. Mice were genotyped, as previously 
described [13, 48]. Tamoxifen was dissolved in sunflower 
oil/ at 20 mg/ml and gavaged at a dose of 60ul/10 g body 
weight daily over 5 consecutive days. On an Applied Bio-
systems 7500 Fast Real Time PCR system in triplicates, 
qPCR was performed using 10 ng of genomic DNA in a 
12.5-μl assay using PowerSYBR Green PCR Master Mix 
(Applied Biosystems). A 167-base-pair Cox10flox-specific 
fragment was obtained with primers 5′-CGG GGA TCA 
ATT CGA GCT CGCC-3′ and 5′-CAC TGA CGC AGC GCC 
AGC ATCTT-3′. All animal experiments were performed in 
compliance with Animals (scientific procedures) Act 1986 
and UK Home Office guidelines under the animal license 
(PPL 70/7872). Tissue from established animal models was 
obtained through collaborations as listed in Table 2.
Both wild type mice and COX10Adv mutant mice of 
C57Bl6 background, aged approximately 13 weeks, were 
anaesthetized using inhalation of 3–4% isoflurane/oxygen 
with supplementation of 0.05 ml of buprenorphine admin-
istered subcutaneously. Following exposure of spinal ver-
tebrae at T12/T13, a dorsal laminectomy was performed to 
expose the dura and the central vein. Dura just lateral to 
the central vein was pierced using a sterile dental needle. 
The tip of a pulled glass capillary, attached to a Hamilton 
syringe, was introduced into the dorsal column through the 
pieced dura at an angle of 45 degree, approximately, and 
0.05 μl of 1% lysolecithin was injected to cause focal demy-
elination of the dorsal column in mice. Wild type mice were 
euthanased at 3, 5, 7 and 9 days post lesioning for the time 
course experiments (Fig. 1) and both wild type mice and 
COX10Adv mice were euthanased at 3 days post lesioning 
for the axon protection experiments (Figs. 3 and 6).
Animal behaviour
Both wild type mice and COX10Adv mutant mice of C57Bl6 
background were subjected to no more than two behavioral 
tests, following a period of training. Animal in the survival 
experiment that reached a moderate severity as defined in 
the project license were culled using a Schedule 1 method.
Electron microscopy of mouse spinal cord
Mice were euthanized using an overdose of pentobarbi-
tone (200 mg/ml) and perfused intravascularly with 2.5% 
glutaraldehyde and 4% paraformaldehyde in 0.1 M sodium 
cacodylate buffer. Following post fixing of the spinal 
cord, tissue was prepared, embedded in Durcupan resin 
and stained, as previously described [63]. A JEOL JEM-
1400 Plus transmission electron microscope was used with 
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Gatan one view digital camera and Digital Micrograph 3 
software at × 5700 magnification to image dorsal column 
axons in cross section. To calculate the g ratio, the cross-
sectional area of the axon, both including and excluding 
myelin ring, was determined using the freehand tool on 
ImageJ software, which enable the radius of the axon and 
radius of the axon plus myelin ring to be calculated to 
determine the g-ratio. At least 100 dorsal column axons 
in the gracile fasciculus in the thoracic spinal cord were 
included for each mouse.
Synaptoneurosome preparation and measurement 
of  Ca2+ fluorescence responses
To investigate whether COX10 deficiency or focal dorsal 
column demyelination impact on neurotransmission at the 
first central synapses of DRG neurons, we prepared synap-
toneurosomes from dorsal column nuclei (DCN) [24, 73]. 
Protocols that optimise metabolic and ionic integrity in syn-
aptoneurosomes have been recently developed in our labo-
ratory so dynamic  Ca2+ fluorescence responses to receptor 
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stimuli can be measured [43, 68, 74]. The selective AMPA 
receptor agonist, R,S-AMPA (Abcam) with the selective 
inhibitor of AMPA receptor desensitization, cyclothiazide 
(Tocris) or the  Ca2+ ionophore, ionomycin (Abcam), were 
added immediately before recording. Intracellular  Ca2+ fluo-
rescence was read at excitation 488 nm, emission 518 nm. 
Ionomycin (10 µM) and basal measurements were included 
in every plate to calibrate the dynamic range of the assay. 
Mean responses were calculated over the first 4 min follow-
ing drug addition.
Statistical analysis
GraphPad  Prism® software, version 6.0 (GraphPad Software 
Inc, US) was used for statistical analysis. For normally dis-
tributed data a two-way student’s t test was used to determine 
statistical significance, while One-way ANOVA was used for 
multiple column comparisons. For data that was not normally 
distributed the two-tailed ‘Mann–Whitney U’ test was selected 
as a non-parametric test, while multiple column comparisons 
were done by using the Kruskal–Wallis test. Unless otherwise 
specified, data is represented as the average ± standard devia-
tion (SD). A p value < 0.05 was regarded as being significant 
and designated *–**** in the graphs.
Results
Mitochondria mobilise from the neuronal cell body 
to the axon, increasing mitochondrial content 
following demyelination: the axonal response 
of mitochondria to demyelination (ARMD)
We hypothesized that mitochondria within healthy neuronal 
cell bodies might respond to demyelination by moving to 
the axon. We therefore labeled mitochondria with a pho-
toconvertible protein (mito-mEOS2) and performed live 
imaging over 20 min to visualise mitochondria that enter 
the myelinated and demyelinated axons from the cell body 
in cerebellar slices (Fig. 1a and Supplementary Fig. 1, online 
resource). Following photoconversion of axonal mitochon-
dria, we identified a large increase in the number of uncon-
verted mitochondria moving from the Purkinje cell body 
to the proximal axon segment upon demyelination (Fig. 1c, 
e–g and videos 6–10, online resource), compared to control 
(Fig. 1b, d, f–g and videos 1–5, online resource). Further-
more, the motile mitochondria displayed a greater antero-
grade speed in demyelinated axons compared with myeli-
nated axons (Fig. 1h). These effects of demyelination on 
axonal mitochondria are not an artefact of the demyelinat-
ing agent, lysolecithin, since it did not significantly impact 
mitochondrial movement in Shiverer mice where axons lack 
myelin (Supplementary Fig. 2, online resource) [10, 28]. 
To assess this mitochondrial response from cell body to the 
demyelinated axon in another neuronal subtype, we cultured 
DRG neurons in the cell body compartment of microfluidic 
chambers, myelinated their axons in a separate chamber, 
induced demyelination by exposing axonal compartment to 
lysolecithin and again found evidence of increased mito-
chondrial mobilisation from the neuronal cell body to the 
axon and increased axonal mitochondrial content (Supple-
mentary Fig. 3, online resource). We term this homeostatic 
response the “axonal response of mitochondria to demyeli-
nation” (ARMD).
The homeostatic ARMD is not sufficient to protect 
acutely demyelinated axons from degeneration
Because the increased transport of mitochondria from the 
neuronal cell body to the axon upon demyelination requires 
Fig. 1  Demyelination mobilises mitochondria from the neuronal cell 
body to the axon and gradually increases the axonal mitochondrial 
content. a Mitochondria within Purkinje cells are labelled in live cer-
ebellar slice cultures, using lentivirus-mitochondria-targeted mEOS2 
(ai, green). Photoconversion of mitochondria within the proximal 
axon segment adjacent to the Purkinje cell body [green to red con-
version in the region of interest (ROI) shown in aii–iv], enables the 
tracking of mitochondria from the cell body to the axon (anterograde, 
left to right). b-c Following photoconversion, time lapse imaging of 
the ROI over 20 min shows newly transported mitochondria (green) 
amongst the photoconverted mitochondria (red) in a myelinated axon 
(b) and a demyelinated axon (c). SCoRe was used to determine the 
myelination status of the mEOS2 labeled axons (Supplementary 
Fig.  1, online resource). The majority of the photoconverted mito-
chondria remained stationary (b, c, red), while the newly transported 
mitochondria to the axon (b, c, green) continued to move (see videos 
for confirmation, online resource) and sometimes co-localised with 
the stationary mitochondria (presumably fused). d, e Kymographs 
of the green fluorescence channel show an abundance of mitochon-
dria moving from the cell body to the ROI (left to right, anterograde 
transport) in demyelinated axons (e) compared with myelinated axons 
(d). See videos 1–5, online resource, for myelinated axons and vid-
eos 6–10, online resource, for demyelinated axons. f–h Quantitation 
of newly transported mitochondria (green) from the cell body to the 
ROI shows a significant increase in the number (f), area (g) and speed 
(h) of motile mitochondria in the demyelinated axons compared 
with myelinated axons. The number of retrograde moving mitochon-
dria from the distal demyelinated axon segment to the ROI is also 
significantly increased upon demyelination (f). Data presented as 
dot-plot with mean (bar) ± standard deviation (whiskers). *p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001 using Mann–Whitney 
U test. i, j Mitochondrial content of acutely demyelinated and non-
transected axons gradually increases and peaks at 5 days in cerebel-
lar slice cultures, following exposure to lysolecithin for 17 h (i). The 
same peak is observed at 7  days, in  vivo, following focal lysoleci-
thin injection to the spinal cord (dorsal columns) of wild type mice 
(j). Each data point indicates the mean value of 20 axons from slice 
preparations or each animal. Statistical significance was determined 
using Kruskal–Wallis test. k, l Axonal injury following demyelina-
tion, judged by axon bulbs (transected axons), peaks 2–4 days earlier 
than the mitochondrial content in demyelinated axons in both cerebel-
lar slices (k) and in vivo (l). Statistical significance was determined 
using Kruskal–Wallis test. ARMD: axonal mitochondrial response to 
demyelination
◂
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Fig. 2  Enhanced mobilisation of mitochondria from the neuronal cell 
body to the axon by over-expression of Miro1 and targeting PGC1α/
PPAR-γ pathway. a Following photoconversion of the mEOS2 
labeled mitochondria in the proximal axon segment (green–red), time 
lapse images indicate the anterograde movement of newly transported 
mitochondria from the unmyelinated DRG neuronal cell body to the 
proximal axon segment (left to right, see videos, online resource). 
Over-expression of Mitochondrial Rho GTPase 1 (Miro1) and per-
oxisome proliferator-activated receptor gamma coactivator 1-alpha 
(PGC1α) in DRG neurons in culture using lentiviruses as well as 
exposure of DRG neurons to 2 µM pioglitazone, a thiazolidinedione, 
enhances anterograde transport of mitochondria, as shown in kymo-
graphs and videos, online resource. b–d Quantitation of the newly 
transported mitochondria in the proximal axon segment of unmy-
elinated axons (green) indicates a significant increase in the number 
of mitochondria mobilising from the DRG neuronal cell body to the 
proximal axon segment following over-expression of Miro1 (b) and 
PGC1α (c) and exposure to pioglitazone (d) compared with untreated 
DRG neurons (ctl: control). The speed of anterograde moving mito-
chondria is significantly greater with the over-expression of PGC1α 
and exposure to pioglitazone. The size of the anterograde moving 
mitochondria remained unchanged. Unlike Miro1, both PGC1α over-
expression in DRG neurons and exposure to 2 µM pioglitazone sig-
nificantly increase the size of the stationary mitochondria (red), and 
the total axonal mitochondrial content. e–g PGC1α and Miro1 over-
expression as well as the application of pioglitazone to DRG neurons 
did not significantly alter the anterograde and retrograde transport of 
lysosomes within unmyelinated axons. h-j Similar to unmyelinated 
axons, Miro1 over-expression does not significantly alter the mito-
chondrial content within myelinated axons, whilst both PGC1α over-
expression and application of pioglitazone significantly increase the 
axonal mitochondrial content within myelinated axons, in vitro. Data 
presented as dot-plot with mean (bar) ± standard deviation (whisk-
ers). *p < 0.05, **p < 0.01 and ***p < 0.001 using Mann–Whitney U 
test once Kruskal–Wallis test showed a p < 0.05 in multiple subgroup 
comparisons
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time to build up axon mitochondrial content in the demyeli-
nated axon we quantitated changes in axonal mitochondrial 
content over time. ARMD peaked at 5 days post demyelina-
tion in cerebellar slices and at 7 days post demyelination of 
centrally projecting dorsal column axons of DRG neurons, 
in vivo. To examine the impact of ARMD on axonal health, 
we compared the temporal changes of axonal degeneration, 
indicated by the formation of axonal bulbs [70], with that 
of axonal mitochondrial content (Fig. 1i–l). In both demy-
elinated cerebellar slices and the centrally projecting dor-
sal column axons of DRG neurons in vivo, transection of 
Purkinje cell and DRG axons occurred 2–4 days prior to the 
peak of ARMD (Fig. 1i–l). We conclude that the acutely 
demyelinated axon is particularly vulnerable for at least 
2–4 days, until ARMD reaches its peak, signifying a poten-
tially short therapeutic window for neuroprotection.
Targeting mitochondrial dynamics and biogenesis 
increases the mobilisation of mitochondria 
from neuronal cell body to the axon
Given that the movement of mitochondria from the neuronal 
cell body to increase the mitochondrial content of the acutely 
demyelinated axon is a relatively protracted process com-
pared with the rapid degeneration of the axon, we aimed to 
determine whether the influx of mitochondria from the cell 
body to the axon can be increased. We first over-expressed 
Mitochondrial Rho GTPase1 (Miro1), which is known to 
facilitate mitochondrial transport by tethering mitochondria 
to a motor/adaptor protein complex [22], and found that this 
significantly increased the movement of mitochondria from 
the cell body to the axon in unmyelinated DRG neurons 
(Fig. 2a, b), as expected [61]. However, targeting mitochon-
drial transport alone did not significantly affect the total 
mitochondrial content of the axons, due to the large num-
ber of stationary mitochondria present there (Fig. 2biv–v). 
Therefore, we aimed to stimulate mitochondrial biogenesis 
in neurons by over-expressing the peroxisome proliferator-
activated receptor gamma (PPAR-γ) coactivator 1-alpha 
(PGC1α), which is the master regulator of mitochondrial 
biogenesis (Fig. 2c) [44, 75]. Over-expression of PGC1α in 
DRG neurons led to increased anterograde mitochondrial 
transport and increased mitochondrial axonal content, thus 
mimicking ARMD. The result of the genetic manipula-
tion was recapitulated upon pharmacological application 
of pioglitazone, an established PGC1α pathway agonist 
(Fig. 2d) [44]. These findings were specific to mitochondria, 
since lysosomal transport was unaffected (Fig. 2e). We next 
examined mitochondrial content in myelinated axons fol-
lowing over-expression of Miro1, PGC1α and application 
of pioglitazone, and found similar changes to unmyelinated 
axons (Fig. 2h–j). Taken together, these findings indicate the 
potential of targeting mitochondrial dynamics and biogen-
esis in neurons to enhance ARMD.
Promoting ARMD in healthy neurons protects 
the acutely demyelinated axons from degeneration
We next assessed whether enhancing the mobilisation of mito-
chondria from the neuronal cell body to the axon alone or 
in combination with increased biogenesis could protect the 
acutely demyelinated axons from degeneration in three experi-
mental systems. First, we found that the over-expression of 
Miro1, PGC1α, or the application of pioglitazone specifically 
to the DRG neuronal cell bodies in microfluidic chambers, 
significantly decreased the fragmentation of acutely demyeli-
nated axons and significantly increased the number of intact 
demyelinated axons (Fig. 3a–c). Addition of a PGC1α inhibi-
tor to the neuronal cell body chamber together with piogl-
itazone reversed the protective effect of pioglitazone treat-
ment on demyelinated axons, implicating PGC1α pathway 
in pioglitazone induced neuroprotection (Fig. 3c). We also 
applied pioglitazone to cerebellar slice cultures and noted a 
significant increase in the axonal mitochondrial content and a 
significant decrease in axonal degeneration following demy-
elination (Fig. 3d–f). We next administered pioglitazone to 
wild type mice for 6 weeks prior to focal demyelination of 
the dorsal columns and found a significantly decreased axonal 
bulb formation with treatment (Fig. 3j–l). Given the pleiotropic 
effects of pioglitazone, we investigated whether expression of 
its target, PGC1α, was affected in DRG neurons and found a 
significant increase of PGC1α + nuclei in DRG neurons with 
treatment (Supplementary Fig. 4, online resource). In keep-
ing with in vitro findings in DRG neurons following over 
expression of PGC1α and pioglitazone treatment, we found 
a significant increase in mitochondria content within axons, 
in vivo, with pioglitazone treatment (Fig. 3m). Taken together, 
these in vitro and in vivo findings indicate that the increased 
mobilisation of mitochondria from the neuronal cell body to 
the axon by targeting of PGC1α pathway and over-expression 
of Miro1 enhances ARMD in wild type neurons and protects 
acutely demyelinated axons from degeneration.
Dorsal root ganglia neurons in progressive 
multiple sclerosis display complex IV deficiency 
and an increase in mitochondrial content 
in demyelinated axons
In disease states, such as progressive MS, there is perturba-
tion to the function of mitochondria in neurons, exempli-
fied by complex IV deficiency, the terminal complex of the 
electron transport chain. Complex IV deficiency is known 
to impair anterograde mitochondrial transport in myelinated 
axons and deplete the mitochondrial content of myelinated 
axons [6, 9, 14, 32, 33, 53, 78]. This raises the question 
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whether mitochondria in these complex IV deficient neurons 
in disease states can respond to demyelination. Therefore, 
we wanted to test the relevance of ARMD to demyelinating 
diseases with complex IV deficient neurons, by examining 
respiratory deficient DRG neurons in MS autopsy tissue and 
the mitochondrial parameters of their demyelinated axons at 
the dorsal root entry zone [6, 9, 14, 78].
We studied DRG neuronal cell bodies and their demy-
elinated centrally projecting axons in the spinal cord dorsal 
columns in progressive MS, as this enabled us to accurately 
identify mitochondria in cell bodies and associated demy-
elinated axons (Table 1). We found approximately one third 
of neuronal cell bodies in DRG of MS to be complex IV 
deficient (Fig. 4a–c) due to clonally expanded mitochondrial 
DNA deletions (Supplementary Fig. 5, online resource). 
Histological analysis of DRG in MS revealed a significant 
increase in the number of HLA + and GFAP + cells while the 
neuronal cell body count did not differ significantly between 
MS and controls, indicating a reactive milieu (Supplemen-
tary Fig. 6, online resource). In 6 out of 18 progressive MS 
cases, we identified chronically demyelinated axons in dorsal 
columns at the dorsal root entry zone (Fig. 4d), and found 
positive correlations between the percentage of complex IV 
deficient proprioceptive neuronal cell bodies in the DRG 
and the mitochondrial content, mitochondrial area, mito-
chondrial number and impaired complex IV in associated 
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demyelinated dorsal column axons (Fig. 4d). This statisti-
cal association indicates that complex IV deficient neuronal 
cell bodies, harboring clonally expanded mtDNA deletion, 
respond to demyelination by mobilising mitochondria to the 
axon, despite their respiratory deficiency.
Existing animal models of MS lack complex IV 
deficient neurons and complex IV knockout mice 
exhibit the ARMD
To investigate ARMD in complex IV deficient neurons, we 
studied 9 distinct experimental models of demyelination 
that are pertinent to MS and a model of traumatic axonal 
transection (Table 2). However, we did not find complex IV 
deficient neurons within the brain, spinal cord or DRG in 
any of these models (Supplementary Fig. 7, online resource) 
and mitochondrial DNA deletions were rarely detected in 
any of these animal models (Supplementary Fig. 8, online 
resource). Therefore, to model the complex IV deficient 
DRG neurons that are observed in MS, we developed a 
neuron-specific inducible mitochondrial mutant by knock-
ing out complex IV subunit 10 (COX10 or protohaem IX 
farnesyltransferase) in DRG neurons (COX10Adv mutant 
mice, Fig. 5) [13, 31]. In 13 week old COX10Adv mutants, 
59% of proprioceptive DRG neurons were complex IV defi-
cient (Fig. 5c), but showed no signs of behavioral disruption 
or neurodegeneration (Supplementary Fig. 9 + 10, online 
resource). Similar to the observations in MS autopsy tissue, 
we found that mitochondrial content, area and complex IV 
deficiency was significantly increased in demyelinated axons 
in COX10Adv mutant mice (Fig. 5l–o). Mitochondrial con-
tent of myelinated axons did not significantly differ in COX-
10Adv mutant mice compared with controls (Supplementary 
Fig. 11, online resource). The fact that the ARMD occurs 
in complex IV deficient neurons in an experimental model 
provided us with the opportunity to test whether enhanc-
ing ARMD can protect these demyelinated axons, which are 
acutely vulnerable to degeneration.
Promoting ARMD in complex IV deficient neurons 
is neuroprotective
Given that complex IV deficient neurons demonstrate 
ARMD, we tested whether transport of mitochondria from 
complex IV deficient neuronal cell bodies to the axon can 
be enhanced by targeting mitochondrial over-expression 
of Miro1, PGC1α and pioglitazone treatment. We inhib-
ited complex IV and therefore mitochondrial respiration 
in mature DRG neurons, in vitro, by using sodium azide 
(SA), which resulted in a significantly decreased antero-
grade transport of mitochondria, as expected (Fig. 6a–c) 
[39]. Strikingly, over-expression of Miro1 or PGC1α and 
treatment with pioglitazone overcame the anterograde mito-
chondrial transport deficit present in complex IV deficient 
neurons (Fig. 6e, f). Furthermore, targeting mitochondrial 
biogenesis with PGC1α over-expression and pioglitazone 
treatment limited the SA induced inhibition of mitochondrial 
respiration, presumably due to the increased mitochondrial 
content in neurons (Fig. 6d and Supplementary Fig. 12, 
Fig. 3  Enhancement of ARMD in wild type neurons, in  vitro and 
in  vivo, protects the acutely demyelinated axons. a, b We labelled 
dorsal root ganglia (DRG) neurons by applying lentivirus-mKate2 
(red) to the cell body chamber while MBP produced by oligoden-
drocytes in the other chamber were labeled using lentivirus M1-M4 
(green) (a, b). Prior to demyelination (pre-DM), live images identify 
myelinated axonal segments in the co-culture chamber (ai and bi, 
arrows). Following demyelination (post-DM), by exposing to lysol-
ecithin for 2 h, live imaging shows damaged MBP-positive structures 
(aii and bii, arrows). We then targeted mitochondria in neurons by 
applying lentivirus-Miro1, lentivirus-PGC1α and pioglitazone to the 
neuronal cell body chamber (treated, shown in bi and bii), prior to 
demyelination. All three manipulations protected the acutely demy-
elinated axonal segments (b, red) compared with untreated co-culture 
chambers (a, red). c For quantitation, axons were identified as intact 
(green outlined bar charts), beaded (orange outlined bar charts) and 
fragmented (red outlined bar charts) based on mKate2 signal, both 
prior to and following demyelination. Quantitation of axon injury 
following demyelination revealed a significant decrease in the pro-
portion of demyelinated axons that are fragmented and a significant 
increase in demyelinated axons that remain intact, when the neuronal 
cell bodies were exposed to lentivirus-Miro1, lentiviris-PGC1α and 
pioglitazone (c). PGC1α inhibitor significantly diminished the pro-
tective effect of pioglitazone on demyelinated axons. Controls shown 
were exposed to lentivirus-mKate2. *p < 0.05 and **p < 0.01 using 
Mann–Whitney U test, once Kruskal–Wallis test showed a p < 0.05 
in multiple subgroup comparisons.dD–i We detected axon bulbs (d, 
insert) when cerebellar slice cultures were demyelinated using lysol-
ecithin (0.5 mg/ml) for 17 h (d). Application of 40 μM pioglitazone 
to cerebellar slice cultures prior to lysolecithin-induced demyelina-
tion significantly decreased the extent of axon bulb formation com-
pared with solvent (DMSO) only controls (f). Axonal mitochondrial 
content increased upon demyelination of cerebellar slices (g, h), con-
sistent with homeostatic ARMD. The application of pioglitazone sig-
nificantly increased the mitochondrial content of myelinated axons (i, 
pioglit + lyso-), compared with untreated cerebellar slices (i, pioglit-
lyso-). ***p < 0.001 using Mann–Whitney U test. j–m Demyelina-
tion of the spinal cord of wild type mice in vivo, using focal injec-
tion of lysolecithin (DM pioglit-) to the dorsal column, increases 
axon bulb formation (j) compared with non-demyelinated wild type 
mice (not shown) at 3  days post lesioning. Pioglitazone in diet for 
6  weeks (120  mg/kg diet), prior to focal spinal cord demyelination, 
significantly decreased axon bulb formation in wild type mice (k, DM 
pioglit + and l) compared with controls on chow diet (j, DM pioglit- 
and l). We did not detect a significant change in DAPI + cells and 
Iba1 + cells in lesions with pioglitazone treatment (Supplementary 
Fig.  14, online resource). Mitochondrial content of both myelinated 
(m, DM-) and demyelinated axons (m, DM +) significantly increased 
following dietary pioglitazone in wild type mice (m, pioglit +) com-
pared with control (m, pioglit-). Data presented as dot-plot with 
mean (bar) ± standard deviation (whiskers). *p < 0.05 and **p < 0.01 
using Mann–Whitney U test. DM demyelinated, MBP myelin basic 
protein, NF neurofilament, Pioglit pioglitazone
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online resource) [44]. Finally, we tested whether enhancing 
the ARMD in complex IV deficient neurons may also be 
neuroprotective, in vivo, in the context of demyelination. 
Consistent with our in vitro findings, the treatment of COX-
10Adv mutant mice with dietary pioglitazone for 6 weeks 
significantly increased axonal mitochondrial content and the 
percentage of proprioceptive neurons with PGC1α-positive 
nuclei (Supplementary Fig. 13, online resource). Dietary 
pioglitazone neither change the number of nuclei, identified 
by DAPI staining, nor the number of Iba1 positive microglia 
in focal lesions, although there was a trend towards decreas-
ing Iba1 positive microglia with treatment (Supplementary 
Fig. 14, online resource) [46, 66]. Strikingly, the increased 
mobilisation of mitochondria in complex IV deficient neu-
rons and axonal mitochondrial content, by pioglitazone treat-
ment, protected the acutely demyelinated axons as evident 
by the significant decrease in acutely transected axons in 
demyelinated lesions (Fig. 6g–i).
To determine whether the protection of acutely demyeli-
nated axons in COX10Adv mutant mice affects functional 
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connectivity, we evaluated the excitability of the first central 
synapses of the dorsal column axons in the dorsal column 
nuclei (DCN). We isolated functionally intact synapses from 
DCN, using synaptoneurosomal preparations, and exposed to 
AMPA receptor agonists to assess  Ca2+ responses. AMPA-
induced  Ca2+ fluorescence responses of freshly prepared 
DCN synaptoneurosomes were significantly reduced in 
COX10Adv mutant mice compared to wild type controls and 
the deficit was exacerbated 3 days following dorsal column 
demyelination (Fig. 6j). Importantly, pioglitazone treatment 
significantly improved the excitability of DCN synaptoneu-
rosome derived from the complex IV deficient neurons that 
were experimentally demyelinated (Fig. 6j). Thus, pioglita-
zone treatment protects not only the structural integrity of 
acutely demyelinated axons in COX10Adv mutant mice, but 
also downstream synaptic function.
Discussion
We propose a novel model (Fig. 7) based on our finding 
that demyelination per se creates a relative shortfall in the 
energy producing capacity, through the inability of the axon 
to rapidly increase its mitochondrial content; thus, the axon 
is not able to meet the increased energy demand that fol-
lows the loss of myelin. Myelination is associated with a 
decrease in axonal mitochondrial content, as evidenced in 
myelinated optic nerve axons and unmyelinated axonal seg-
ments in lamina cribrosa as well as dysmyelinated axons in 
Shiverer mice (Fig. 7a–b, e) [3, 5]. Upon demyelination, we 
discovered that mitochondria mobilise from neuronal cell 
body to the acutely demyelinated axons, which slowly build 
up their mitochondrial content through ARMD (Fig. 7b–c, 
f). Although the neuronal cell body attempts to energetically 
support the demyelinated axon, by increasing the transport 
of mitochondria to the axon, the peak of ARMD lags behind 
the peak of axon transection by a number of days. Thus, the 
homeostatic response of ARMD is insufficient to correct 
the resulting energy imbalance created by demyelination 
(Fig. 7f). By targeting mitochondrial biogenesis and antero-
grade transport to enhance ARMD, we identify a novel ther-
apeutic strategy to protect the acutely demyelinated axons 
(Fig. 7c–d, g).
Currently, there is no effective neuroprotective therapy 
for demyelinating disorders, including MS. One strategy 
is to curtail the increased energy demand of demyelinated 
axon through drugs that inhibit sodium channels. Although 
effective in experimental models, these have failed in clini-
cal trials and are poorly tolerated by MS patients [27, 76]. 
This is perhaps not surprising because they perturb adap-
tive neuronal firing properties that are required for healthy 
functioning. An alternative strategy, which we show here, is 
to boost the energy producing capacity of the demyelinated 
axon. Previous studies have shown that axonal mitochon-
drial transport can be increased by targeting mitochondrial 
biogenesis, through PGC1α over expression, as a potential 
therapy for neurodegenerative disorders [50].This potential 
therapeutic strategy, however, has not been applied to demy-
elinating disorders. We show that an increased transport of 
mitochondria from the neuronal cell body to axon makes 
ARMD more efficient and protects the acutely demyeli-
nated axon. Given the suboptimal nature of the homeostatic 
ARMD, the strategy of increasing mitochondrial biogenesis 
and axonal transport is ideally suited for demyelinating dis-
orders. Hence, our findings provide a mechanism that can 
be therapeutically targeted—within the necessary short time 
frame—for neuroprotection in demyelinating disorders.
Notwithstanding the prevalence of sensory symptoms, 
including impaired joint position sensation and increased 
sensitivity to painful stimuli in MS, coupled with the 
Fig. 4  Respiratory deficient neurons are prevalent within dorsal root 
ganglia in progressive MS and their percentage positively correlates 
with mitochondrial content, size, number and complex IV deficiency 
in demyelinated dorsal column axons. a, b In progressive MS, dor-
sal root ganglia (DRG) neurons that lack mitochondrial complex IV 
and contain complex II (stained blue by COX/SDH histochemistry, 
insert in b), termed respiratory deficient, are abundant (b) compared 
with controls (a). The majority of neurons show intact complex IV in 
controls (stained brown, insert in a). c Quantitation of DRG in pro-
gressive MS identified significantly more respiratory deficient neu-
rons in lumbar DRGs compared with controls (p < 0.0001). Respira-
tory deficient neurons tended to be more prevalent in lumbar DRG 
than cervical DRG [the broken lines (c) indicate data from the same 
case]. In Parkinson’s disease the mean respiratory deficient neurons 
in lumbar DRG is 28.77% (SD = 13.66, n = 3) and the mean is 33.51% 
(SD = 13.66, n = 2) in motor neuron disease (MND) lumbar DRG 
(not shown). Data presented as dot-plot with mean (bar) ± standard 
deviation (whiskers). ****p < 0.0001 using Mann–Whitney U test 
and Kruskal–Wallis test showed a p < 0.0001 in multiple subgroup 
comparisons. Chronic spinal cord lesions in dorsal columns, at the 
corresponding dorsal root entry zone, of six progressive MS cases 
enabled the impact of respiratory deficient neurons on the mitochon-
drial parameters of demyelinated axons to be assessed. d Mitochon-
drial content in demyelinated dorsal column axons at the root entry 
zone, as a percentage of axon area, correlated significantly (p = 0.004, 
r2 = 0.904) and positively with the percentage of respiratory deficient 
proprioceptive neurons in lumbar DRG in progressive MS (di). Aver-
age size of mitochondria within demyelinated dorsal column axons 
correlated significantly (p = 0.044, r2 = 0.677) and positively with the 
percentage of respiratory deficient proprioceptive neurons in lum-
bar DRG in progressive MS (dii). Average number of mitochondria 
within demyelinated dorsal column axons at the root entry zone cor-
related significantly (p = 0.026, r2 = 0.747) and positively with the 
percentage of respiratory deficient proprioceptive neurons in lumbar 
DRG in progressive MS (diii). As expected, the percentage of the 
axon occupied by mitochondria that lacked complex IV subunit-I cor-
related significantly (p = 0.023, r2 = 0.763) with the percentage of res-
piratory deficient proprioceptive neurons in lumbar DRG in progres-
sive MS (div)
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prediction of metabolic and molecular perturbations in the 
MS DRG, it is surprising that DRG neurons have not been 
hitherto studied [69]. We performed a detailed analysis of 
mitochondria in DRG neuronal cell bodies from 18 pro-
gressive MS autopsy cases and 12 controls. Furthermore, 
we correlated mitochondrial changes within DRG neuronal 
cell bodies with mitochondrial changes within demyelinated 
axons, at the dorsal root entry zone, in spinal cord blocks. 
Complex IV deficiency and clonally expanded mtDNA dele-
tions in DRG neurons, as observed in this study, are similar 
to those seen in cortical neurons and choroid plexus epithe-
lial cells in MS, although the respiratory deficiency affected 
a greater proportion of neurons in the DRG [7, 9]. These 
findings show that there are factors other than the energy 
shortfall due to the time lag of ARMD and inflammation 
induced damage to mitochondria, which are intrinsic to the 
neuron that contribute to the energy deficit of the demyeli-
nated axon. MtDNA deletion in single cells is not a reflec-
tion of the accumulation of ongoing damage to mtDNA. 
Clonal expansion of mtDNA is an active phenomenon that 
amplifies a mtDNA deletion in a single cell, as evidenced 
in a number of neurodegenerative disorders, including MS 
[29]. In MS, mtDNA deletions appear to be induced by 
the inflammatory process, as we did not find changes, in 
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excess of age, in skeletal muscle from progressive MS cases. 
These mtDNA deletions then undergo amplification through 
clonal expansion in metabolically highly active cells such 
as neurons and choroid plexus epithelial cells [8]. Given 
the clonally expanded mtDNA deletions in DRG neurons, 
together with the significant positive correlation between 
the extent of complex IV deficiency in proprioceptive DRG 
neuronal cell bodies and axonal mitochondrial content, we 
suggest that complex IV deficient neurons attempt to trig-
ger ARMD even more vigorously than neurons with healthy 
mitochondria.
The failure to identify respiratory deficient neurons in the 
brain, spinal cord and DRG following a detailed examina-
tion in nine experimental disease models, and tissue from 
spinal cord hemi-section, highlights a major shortfall of the 
existing disease models in recapitulating neuropathologi-
cal findings of progressive MS. There are multiple poten-
tial reasons for the lack of respiratory deficient neurons in 
existing models. First, oxidative injury that is implicated in 
the induction of mtDNA deletions is limited in established 
disease models compared with MS [60]. Second, these 
experimental disease models predominantly adopt young 
animals, which may have better repair and mitochondrial 
quality control mechanisms. Third, the clinicopathologi-
cal course of animal models is relatively short compared 
with the disease duration of progressive MS. Finally, both 
chronic and ongoing acute demyelination, as evidenced in 
slowly expanding MS lesions, are relatively sparse in exist-
ing disease models compared with progressive MS [19]. 
Although the complex IV knockout mice used in this study 
do not elucidate the causes of mitochondrial perturbations 
in neuronal cell bodies, such models recapitulate the neu-
ronal mitochondrial changes in MS and therefore help to 
determine the consequences of mitochondrial respiratory 
chain deficiency for the demyelinated axons. Our data in 
COX10Adv mutants indicate that the stimulation of mito-
chondrial biogenesis and mitochondrial dynamics can partly 
overcome the detrimental consequences of the complex IV 
deficiency in acutely demyelinated axons. The protective 
effect of increasing mitochondrial biogenesis in complex 
IV deficient neurons is likely to reflect the fact that such 
mitochondria are deficient, but not completely devoid of 
metabolic activity. Therefore, despite their deficiency, they 
exert a net positive effect, and help boost the overall energy 
producing capacity of the axon. We therefore suggest that 
enhancing ARMD is a therapeutically tractable approach, 
particularly when combined with approved therapy in MS 
as well as HIV neuropathy and diabetic neuropathy, where 
complex IV deficiency is an additional contributor to the 
axonal energy failure [6, 9, 14, 78].
In demyelinating disorders, axon degeneration is most 
prominent in areas with acute demyelination. In MS, neuro-
pathological studies have shown that demyelination is ongo-
ing throughout the clinical course of the disease. During the 
early stage of MS, there is an abundant formation of acutely 
demyelinating lesions [19]. In progressive MS, there is still 
ongoing demyelination, particularly at the edge of chronic 
active or slowly expanding lesions even at the end stages of 
MS [19, 35]. MRI imaging provides robust evidence of new 
lesions in early stage and slowly expanding lesions [1, 11, 
19]. In terms of neuronal mitochondria, factors that amplify 
mitochondrial injury, such as oxidative stress and iron accu-
mulation, likely require time to compromise the neurons 
[37]. Our prediction is that respiratory deficiency within 
neurons becomes more prominent with increasing disease 
duration in MS. Thus, our findings in both wild type mice 
and COX10Adv mutant mice show that our neuroprotective 
strategy is applicable to the entire disease course of MS.
Fig. 5  Modeling the complex IV deficient DRG neurons and recapit-
ulating mitochondrial changes within demyelinated axons in progres-
sive MS, in vivo. A–c DRG neuron-specific inducible knockout mice 
that lack protoheme IX farnesyltransferase [subunit 10 of complex IV 
(COX10), termed COX10Adv mutants) contain complex IV deficient 
DRG neurons (b), which are stained blue by the sequential COX/
SDH histochemistry assay. DRG neurons with intact complex IV are 
stained brown in both wild type mice and COX10Adv mutants (a, b). 
The quantitation identified approximately 59% of the DRG neurons 
as respiratory deficient in COX10Adv mice (c, n = 3) compared with 
none in controls (c, n = 3). d–f Sequential COX histochemistry and 
immunofluorescent labeling method, as previously described, identi-
fies both proprioceptive (NF200 + peripherin-, in green) and nocicep-
tive neurons (NF200-peripherin + , in red) in DRG that are respiratory 
deficient (lack of or decrease in intensity of brown staining follow-
ing COX histochemistry, shown in grey scale images in di and ei) in 
COX10Adv mutants (ei), unlike wild type mice (di). The quantitation 
of complex IV within immunofluorescently labeled proprioceptive 
and nociceptive neurons, using densitometry, identifies approximately 
59.33 ± 8.14% and 83.33 ± 3.05% of proprioceptive and nociceptive 
neurons, respectively, in COX10Adv mutants to be lacking complex 
IV (f). Complex IV deficient neurons, judged by densitometric anal-
ysis of COX histochemistry, are not present within DRG from wild 
type mice (a). g: Quantitation of proprioceptive (NF200-positive in 
green) and nociceptive (peripherin-positive in red) DRG neurons 
from 13 week old wild type (n = 3) and COX10Adv mutants (n = 3) 
shows similar proportion of proprioceptive and nociceptive neurons 
in both groups. h–k In focal lysolecithin-induced lesions of the dor-
sal columns, demyelinated axons (NF in blue) contain more mito-
chondria (j, k) than myelinated axons (h, i), when mitochondria are 
identified with complex II 70KDa subunit (red) labeling, in both wild 
type (h, j) and COX10Adv mutants (i, k). As expected, complex IV 
subunit-I (green) is lacking within axonal mitochondria in COX-
10Adv mutants (i, k). l–o Quantitation of mitochondria within demy-
elinated dorsal column axons from wild type mice and COX10Adv 
mutants shows a significantly greater mitochondrial occupancy (l) 
and mitochondrial size (m) as well as extent of mitochondria lack-
ing complex IV subunit-I (o) in experimentally demyelinated COX-
10Adv mutants compared wild type mice. These findings are con-
cordant with the positive correlations that we observed between the 
extent of respiratory deficient proprioceptive neurons and the mito-
chondrial parameters within demyelinated dorsal column axons at 
the root entry zone in progressive MS (shown in e, f). *p < 0.05 and 
***p < 0.001 using Mann–Whitney U test. Data presented as dot-plot 
with mean (bar) ± standard deviation (whiskers)
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Overall, for a neuroprotective strategy such as enhancing 
ARMD to be effective, it has to be combined with effective 
immunomodulatory therapies and with those that restore the 
myelin sheath to axons (remyelination therapy) [18]. The 
mechanisms of axon degeneration, such as by cytotoxic 
T cells mediated axonal transection and by free radical 
mediated damage to mitochondria in both myelinated and 
demyelinated axons require the inflammatory response in 
Fig. 6  Enhancement of ARMD in complex IV deficient neurons pro-
tects the extremely vulnerable acutely demyelinated axons. a–c To 
model complex IV deficiency in  vitro, we pharmacologically inhib-
ited it using sodium azide (SA, at 100 μM for 16 h), which signifi-
cantly decreases complex IV activity in wild type DRG neurons (b, 
c), as expected, compared with controls (a, c). The inhibition of com-
plex IV by SA is similarly effective in DRG neurons, where Miro1 
and PGC1α are over-expressed, using lentiviruses, and when exposed 
to pioglitazone (c). Controls shown were exposed to lentivirus-
mEOS2. Solvent (DMSO) only controls for pioglitazone treatment 
did not show a significant effect compared with lentivirus-mEOS2 
controls without DMSO (not shown). ***p < 0.001 using Mann–
Whitney U test and Kruskal–Wallis test showed a p < 0.05 in multi-
ple subgroup comparisons. d Mitochondrial respiration significantly 
decreases when DRG neurons that are over-expressing Miro1 are 
exposed to SA (100 μM for 16 h) (d). Although mitochondrial respi-
ration tends to decrease when DRG neurons that are over-expressing 
PGC1α and treated with pioglitazone are exposed to SA, the decrease 
is not statistically significant (d), despite the significant inhibition of 
complex IV activity (c). **p < 0.01 using Mann–Whitney U test and 
Kruskal–Wallis test showed a p < 0.05 in multiple subgroup compari-
sons. e, f As expected, the number of mitochondria mobilising from 
the DRG neuronal cell body to the axon significantly decreases fol-
lowing inhibition of complex IV by SA (100 μM for 16 h) compared 
with DRG neurons not exposed to SA. In contrast, SA does not sig-
nificantly decrease the anterograde movement of mitochondria from 
the cell body to the axon in DRG neurons where Miro1 and PGC1α 
are over-expressed, using lentiviruses, and when DRG neurons are 
treated with pioglitazone (e). Kymographs show the improvement in 
the number of mitochondria mobilising from the complex IV defi-
cient neuronal cell body to the axon, which is mediated by Miro1 
(fii), PGC1α (fiii) and pioglitazone (fiv). **p < 0.01 and ***p < 0.001 
using Mann–Whitney U test and Kruskal–Wallis test showed a 
p < 0.05 in multiple subgroup comparisons. g–i When dorsal col-
umn axons are demyelinated (g, DM) by focal lysolecithin injections 
to the dorsal columns of COX10Adv mutant mice with complex 
IV deficient DRG neurons, there is an abundance of axon bulbs at 
3 days post lesioning (g, i). Pioglitazone in diet for 6 weeks (120 mg/
kg diet), prior to focal dorsal column demyelination, significantly 
decreased the axon bulb formation within the demyelinated area in 
COX10Adv mutant mice (h, DM pioglit +) compared with untreated 
COX10Adv mutants (g, DM pioglit-) after focal demyelination of 
dorsal columns (i). *p < 0.05 and **p < 0.01 using Mann–Whitney 
U test. j  Ca2+ fluorescence responses of dorsal column nuclei (DCN) 
synaptoneurosomes evoked by AMPA (40  μM) in the presence of 
cyclothiazide (20  μM) were significantly attenuated in COX10Adv 
mutant mice compared to wild type and the impairment was exacer-
bated in mice with dorsal column demyelination 3  days previously. 
Dietary treatment with pioglitazone for 6 weeks beforehand fully res-
cued the functional deficits. Responses of non-pioglitazone controls 
(treated with DMSO vehicle) showed no significant difference from 
naive controls (**p < 0.01, ***p < 0.001; One-Way ANOVA with 
Tukey’s test, n = 4–10). COX10Adv: Inducible and DRG neuron-spe-
cific (Adv: advillin) knock out of complex IV subunit 10 (COX10) 
in mice, with complex IV deficient DRG neurons. Data presented as 
dot-plot with mean (bar) ± standard deviation (whiskers). DM demy-
elinated, Pioglit pioglitazone, SA sodium azide, complex IV inhibitor. 
*p < 0.05, **p < 0.01 and ***p < 0.001
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MS to be effectively controlled [23, 30, 49, 65]. Whether 
enhancing ARMD protects chronically demyelinated axons 
that are located in chronic inactive lesions or in the inactive 
centre of chronic active lesions is not known. Furthermore, 
whether the supply of metabolic substrate to the axon, that 
is necessary for mitochondrial respiratory chain function, is 
a rate limiting factor in both acutely and chronically demy-
elinated axons is not known [20]. The energy imbalance in 
chronically demyelinated axons can be partially restored by 
remyelination, which decreases the axonal mitochondrial 
content to a level that approaches that found in myelinated 
axons [81]. Remyelination addresses the long term protec-
tion of axons that have survived the acute destruction of 
their myelin sheath (chronically demyelinated axons). In 
contrast, our neuroprotection strategy allows more axons 
to be saved during acute demyelination so that remyelina-
tion may restore the metabolic neuronal-glial cross talk in 
the long term [1, 18, 20]. Thus, our neuroprotective model 
serves to bridge the crucial gap between immune therapy 
and regenerative therapy.
In summary, our findings clearly illustrate a key compen-
satory role for mitochondria as part of the neuronal response 
to demyelination. Although the mobilisation of mitochon-
dria from the neuronal cell body to the axon occurs spon-
taneously following the destruction of myelin, the resultant 
increase in the mitochondrial content of the demyelinated 
axon, which we term homeostatic ARMD, is too protracted. 
Enhancing ARMD, by increasing the transport of mito-
chondria from the neuronal cell body to the axon as well as 
mitochondrial biogenesis in the neuron, protects the acutely 
demyelinated axon. This novel neuroprotective strategy is 
likely to be applicable to all demyelinating disorders, even 
when neurons are respiratory chain deficient. Hence, drugs 
that enhance ARMD are important to protect the vulnerable 
acutely demyelinated axons, so that regenerative strategies, 
like remyelination, can be effectively implemented in demy-
elinating CNS and PNS disorders.
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